Angle PLC Contract announcement with Eisai Inc. (2723Y)
02 Enero 2024 - 1:00AM
UK Regulatory
TIDMAGL
RNS Number : 2723Y
Angle PLC
02 January 2024
For immediate release 2 January 2024
ANGLE plc ("the Company")
CONTRACT ANNOUNCEMENT WITH LARGE PHARMA COMPANY, EISAI INC.
Pilot study for ANGLE's Portrait HER2 assay in Phase II study of
HER2 targeting antibody-drug conjugate, BB-1701
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company with innovative circulating tumour cell (CTC) diagnostic
solutions for use in research, drug development and clinical
oncology, is delighted to announce that it has signed a contract
with the global pharmaceutical company, Eisai Inc. ("Eisai").
Under the agreement, in a pilot study worth US $250,000 to
ANGLE, ANGLE will provide CTC analysis with its Portrait HER2 assay
to assess breast cancer patients' HER2 (human epidermal growth
factor receptor 2) status in a Phase II study of the HER2 targeting
antibody-drug conjugate (ADC) BB-1701. Success in the pilot study
offers the potential for multiple large scale follow-up
studies.
ANGLE's Portrait HER2 assay enables quantitative assessment of
both HER2 protein expression (via IF) and HER2/neu gene
amplification (via FISH) to identify patients who could benefit
from anti-HER2 ADC treatment. HER2-low breast cancer accounts for
55% of all breast cancer cases with analysts predicting that the
global HER2+ breast cancer ADC market will reach US $3.3 billion
per annum by 2030. Because of market expansion into HER2-low
patients, ANGLE has developed a quantitative HER2 assay to enable
accurate stratification of patient populations throughout the
treatment pathway given HER2 status can change over time.
ANGLE Chief Executive Officer, Andrew Newland, commented:
"The use of CTC biomarkers in clinical trials is a rapidly
growing field enabling longitudinal monitoring of genomic,
transcriptomic and proteomic changes. ANGLE's Portrait HER2 assay
provides a way to evaluate HER2 status in patients where a tissue
biopsy at the metastatic site either fails or is not feasible. We
are delighted that Eisai is utilising our new HER2 assay for this
study and believe that a successful pilot study will lead the way
to major expansion of this line of our business going forward."
For further information:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Berenberg (NOMAD and Joint Broker)
Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the EU Market Abuse Regulation (596/2014) . Upon the publication of
this announcement via a regulatory information service, this
information is considered to be in the public domain.
For Research Use Only. Not for use in diagnostic procedures.
For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative
circulating tumour cell (CTC) diagnostic solutions for use in
research, drug development and clinical oncology using a simple
blood sample. ANGLE's FDA cleared and patent protected circulating
tumour cell (CTC) harvesting technology known as the Parsortix(R)
PC1 System enables complete downstream analysis of the sample
including whole cell imaging and proteomic analysis and full
genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on diagnostic
products and clinical services. Diagnostic products include the
Parsortix(R) system and associated consumables. The clinical
services business is offered through ANGLE's GCP-compliant
laboratories. Services include custom made assay development and
clinical trial testing for pharma.
Over 90 peer-reviewed publications have demonstrated the
performance of the Parsortix system. For more information, visit
www.angleplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTBCGDBDGGDGSB
(END) Dow Jones Newswires
January 02, 2024 02:00 ET (07:00 GMT)
Angle (LSE:AGL)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Angle (LSE:AGL)
Gráfica de Acción Histórica
De May 2023 a May 2024